Avenue Therapeutics, Inc. (NASDAQ:ATXI) Sees Large Growth in Short Interest

Avenue Therapeutics, Inc. (NASDAQ:ATXI) saw a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 80,600 shares, an increase of 258.2% from the December 31st total of 22,500 shares. Based on an average daily volume of 358,600 shares, the days-to-cover ratio is currently 0.2 days. Currently, 4.6% of the shares of the stock are sold short.

Avenue Therapeutics Stock Up 3.0 %

Shares of Avenue Therapeutics stock traded up $0.04 during trading hours on Friday, reaching $1.36. 101,545 shares of the company’s stock were exchanged, compared to its average volume of 1,105,412. The business has a fifty day moving average of $1.84 and a two-hundred day moving average of $2.28. The company has a market capitalization of $2.79 million, a P/E ratio of 0.07 and a beta of -0.27. Avenue Therapeutics has a 1 year low of $1.26 and a 1 year high of $15.00.

Institutional Investors Weigh In On Avenue Therapeutics

A hedge fund recently bought a new stake in Avenue Therapeutics stock. Moss Adams Wealth Advisors LLC acquired a new stake in Avenue Therapeutics, Inc. (NASDAQ:ATXI) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 11,000 shares of the company’s stock, valued at approximately $27,000. Moss Adams Wealth Advisors LLC owned 1.17% of Avenue Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 17.34% of the company’s stock.

Avenue Therapeutics Company Profile

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.